Countdown to Insmed (INSM) Q4 Earnings: Wall Street Forecasts for Key MetricsZacks Investment Research • 02/17/25
Insmed (INSM) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseZacks Investment Research • 02/13/25
Insmed to Host Fourth-Quarter and Full-Year 2024 Financial Results Conference Call on Thursday, February 20, 2025PRNewsWire • 02/10/25
FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025PRNewsWire • 02/06/25
Insmed Provides Business Update at 43rd Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/10/25
Insmed (INSM) Reliance on International Sales: What Investors Need to KnowZacks Investment Research • 11/04/24
Insmed's Q3 Loss Wider Than Expected, Sales In Line With EstimatesZacks Investment Research • 11/01/24
Insmed Reports Third-Quarter 2024 Financial Results and Provides Business UpdatePRNewsWire • 10/31/24
Insmed (INSM) Q3 Earnings Preview: What You Should Know Beyond the Headline EstimatesZacks Investment Research • 10/30/24
Insmed Unites Across Communities Around the World During Third Annual Global Day of GoodPRNewsWire • 10/23/24
Insmed to Host Third-Quarter 2024 Financial Results Conference Call on Thursday, October 31, 2024PRNewsWire • 10/17/24
New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population ResultsPRNewsWire • 10/08/24